ALKEMNSEAlkem Laboratories LimitedMediumPositive
Announced Sat, 14 Mar · 15:45 IST

Alkem Laboratories Limited has informed the Exchange about receipt of EU GMP Certificate for the Company s manufacturing facility located at Baddi, India.

Regulatory Product ApprovalBusiness Updates View source PDF

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.6%1-day move
₹5384.00
prior close
₹5393.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.1-1.3-1.1-0.8-0.6-0.4-2.4-1.9-4.2+0.9+0.0+3.3+1.6-0.7
Up moveDown movePending
AI summary

Alkem Laboratories has received an EU GMP Certificate from the German Health Authority (Department of Pharmacy – Human Medicines) for its manufacturing facility located in Baddi, India. This follows an inspection conducted from November 4 to November 10, 2025, which Alkem had previously disclosed on November 10, 2025. The certificate of GMP compliance is valid for 3 years from the date of inspection. With this certification, the Baddi facility is now cleared to manufacture and supply pharmaceutical products to EU-regulated markets. The disclosure has been made under SEBI LODR Regulation 30 and will be posted on the company's website.

Likely market impact

Positive for shareholders — this regulatory clearance strengthens Alkem's ability to serve European markets, supports its export-driven growth strategy, and removes a key compliance overhang that existed since the inspection was first flagged in November 2025.